GO:1903054 negative regulation of extracellular matrix organization: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903054 describes any process that stops, prevents, or reduces the frequency, rate, or extent of extracellular matrix (ECM) organization.
• ECM organization is a dynamic balance between matrix synthesis, assembly, crosslinking, and degradation; negative regulation shifts this balance toward reduced matrix deposition or increased turnover.
• Key negative regulators include secreted antagonists such as SFRP1, matricellular proteins like CCN1, and intracellular signaling modulators such as PTEN.
• Dysregulated negative regulation of ECM organization contributes to fibrosis, cancer progression, and impaired tissue repair.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate negative regulators in relevant cell types.
• Integrating transcriptomics, proteomics, and imaging with CRISPR screens provides a robust framework for dissecting GO:1903054 mechanisms.
Description
The extracellular matrix (ECM) is a complex network of proteins and polysaccharides that provides structural support and biochemical cues to cells. ECM organization encompasses the synthesis, assembly, crosslinking, and remodeling of matrix components, and its dysregulation underlies numerous pathological conditions. The Gene Ontology term GO:1903054, negative regulation of extracellular matrix organization, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of ECM organization. This term is critical for researchers studying tissue homeostasis, fibrosis, cancer, and regenerative medicine because it defines the regulatory mechanisms that restrain excessive matrix deposition or promote matrix turnover. Understanding these negative regulators is essential for identifying therapeutic targets that can reverse pathological ECM accumulation or restore proper tissue architecture.
negative regulation of extracellular matrix organization At A Glance
| GO ID | GO:1903054 |
|---|---|
| GO term | negative regulation of extracellular matrix organization |
| Ontology | biological_process |
| Synonym | down regulation of extracellular matrix organization; inhibition of extracellular matrix organization; negative regulation of extracellular matrix organisation |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of extracellular matrix organization |
| Related processes | Extracellular matrix organization (GO:0030198), regulation of extracellular matrix organization (GO:1903053) |
| Cellular context | Secreted factors, cell surface receptors, intracellular signaling pathways that modulate matrix synthesis and degradation |
| Disease relevance | Fibrosis, cancer, impaired wound healing, tissue remodeling disorders |
What Is GO:1903054?
GO:1903054 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of extracellular matrix organization. In other words, it covers molecular and cellular events that inhibit the assembly, deposition, or remodeling of the ECM, thereby maintaining matrix homeostasis or counteracting pro-fibrotic signals.
Why Is negative regulation of extracellular matrix organization Important in Cell Biology?
Negative regulation of ECM organization is essential for preventing excessive matrix deposition, which is a hallmark of fibrotic diseases and promotes tumor progression. It also plays a role in tissue repair by ensuring timely resolution of matrix remodeling. Understanding the molecular players that negatively regulate ECM organization can reveal therapeutic targets for antifibrotic and anticancer strategies.
• Prevents pathological fibrosis by restraining excessive collagen and matrix deposition.
• Modulates tumor microenvironment and cancer progression by altering ECM stiffness and composition.
• Influences wound healing and tissue regeneration by controlling matrix turnover.
• Regulates cell migration and invasion through matrix remodeling.
• Impacts developmental processes where ECM remodeling is critical.
• Provides targets for antifibrotic therapies in lung, liver, and kidney diseases.
• Affects immune cell infiltration by modifying the ECM barrier.
• Plays a role in cardiovascular repair after myocardial infarction.
• Can be studied using CRISPR screens to identify novel negative regulators.
• Offers biomarkers for prognosis in cancers such as ovarian cancer.
What Happens During negative regulation of extracellular matrix organization?
Inhibition of matrix synthesis
In simple terms: Cells reduce the production of ECM proteins.
Negative regulation of ECM organization can occur through decreased transcription or translation of matrix components such as collagens and fibronectin. For example, secreted frizzled-related protein 1 (SFRP1) inhibits lung fibroblast invasion and transition to myofibroblasts, thereby reducing matrix synthesis during injury responses. This regulation helps prevent excessive scar formation.
Promotion of matrix degradation
In simple terms: Enzymes that break down the matrix are activated.
Matrix metalloproteinases (MMPs) and other proteases degrade ECM components, and their activity can be enhanced by negative regulators. For instance, matricellular protein CCN1 promotes collagen alignment and scar integrity after myocardial infarction, but also modulates matrix turnover. The balance between synthesis and degradation determines net ECM organization.
Interference with matrix assembly and crosslinking
In simple terms: The process of assembling matrix proteins into a stable network is blocked.
Negative regulators can disrupt the assembly of matrix fibrils or inhibit crosslinking enzymes such as lysyl oxidases. Stromal PTEN regulates ECM organization in the mammary gland, and its loss leads to increased matrix deposition and altered organization. Thus, PTEN acts as a negative regulator of ECM organization in this context.
Modulation of cell-matrix interactions
In simple terms: Cells change how they attach to and pull on the matrix.
Integrins and other adhesion receptors mediate cell-ECM interactions, and negative regulators can alter their expression or signaling. Paxillin, a focal adhesion protein, interacts with multiple partners to regulate cell migration and matrix remodeling. Dysregulation of these interactions can affect ECM organization.
Regulation by secreted antagonists and matricellular proteins
In simple terms: Secreted molecules act as brakes on matrix production.
Secreted antagonists such as SFRP1 and matricellular proteins like CCN1 can inhibit pro-fibrotic signaling pathways, reducing ECM organization. These factors often act in a context-dependent manner, influencing both matrix deposition and cell behavior.
Key Genes Involved in GO:1903054 negative regulation of extracellular matrix organization
The following genes and proteins have been implicated in negative regulation of extracellular matrix organization based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SFRP1 | Secreted Wnt antagonist; inhibits fibroblast invasion and myofibroblast transition | Negative regulator of lung fibrosis and ECM organization |
| PTEN | Phosphatase and tensin homolog; regulates stromal ECM organization | Loss leads to increased ECM deposition in mammary gland |
| CCN1 | Matricellular protein; promotes collagen alignment and scar integrity | Modulates ECM organization after myocardial infarction |
| PXN | Paxillin; focal adhesion protein | Regulates cell migration and matrix remodeling |
| MMP2 | Matrix metalloproteinase-2; degrades collagen IV and other ECM components | Promotes matrix turnover, counteracting ECM accumulation |
| MMP9 | Matrix metalloproteinase-9; degrades denatured collagen | Involved in ECM remodeling in various tissues |
| TIMP1 | Tissue inhibitor of metalloproteinases 1; inhibits MMP activity | Can indirectly promote ECM accumulation by inhibiting degradation |
| TIMP2 | Tissue inhibitor of metalloproteinases 2; inhibits MMP activity | Regulates ECM turnover |
| TGFB1 | Transforming growth factor beta 1; pro-fibrotic cytokine | Its inhibition reduces ECM organization; negative regulators often antagonize TGFB1 signaling |
| CTGF | Connective tissue growth factor; promotes ECM synthesis | Target of negative regulation in fibrosis |
| COL1A1 | Collagen type I alpha 1 chain; major ECM component | Its downregulation is a marker of negative regulation of ECM organization |
| FN1 | Fibronectin 1; ECM glycoprotein | Involved in matrix assembly and remodeling |
| ITGB1 | Integrin beta 1; cell-ECM adhesion receptor | Mediates cell-matrix interactions affected by negative regulators |
| LAMA1 | Laminin subunit alpha 1; basement membrane component | ECM organization target |
| SPARC | Secreted protein acidic and cysteine rich; matricellular protein | Modulates ECM assembly and cell-matrix interactions |
| POSTN | Periostin; matricellular protein | Involved in ECM remodeling in fibrosis and cancer |
| MMP14 | Matrix metalloproteinase-14; membrane-type MMP | Activates other MMPs and degrades ECM |
How Is negative regulation of extracellular matrix organization Regulated?
Negative regulation of ECM organization is controlled by a network of signaling pathways, including Wnt, TGF-beta, and PTEN/PI3K/AKT. SFRP1 inhibits Wnt signaling, reducing fibroblast activation and ECM deposition. PTEN loss leads to increased ECM organization in the mammary gland, indicating that PTEN negatively regulates this process. CCN1 modulates matrix organization after myocardial infarction, partly through integrin signaling. These pathways converge on transcriptional programs that control matrix gene expression and protease activity.
negative regulation of extracellular matrix organization and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SFRP1 | Lung fibrosis | Knockout mouse lung fibroblasts; overexpression in human lung fibroblasts |
| PTEN | Breast cancer / mammary gland ECM organization | Stromal PTEN knockout mouse; mammary epithelial cells |
| CCN1 | Myocardial infarction | CCN1 knockout or overexpression in cardiac fibroblasts |
| MMP2 | Fibrosis / cancer invasion | MMP2 knockout mice; cancer cell lines |
| PXN | Cell migration / matrix remodeling | Paxillin knockout fibroblasts; point mutations |
Fibrosis
Excessive ECM deposition is a hallmark of fibrosis in lung, liver, kidney, and heart. Negative regulators such as SFRP1 counteract fibroblast activation and matrix production, and their loss contributes to fibrotic progression. Targeting these negative regulators could restore matrix homeostasis.
Cancer
The tumor microenvironment ECM influences cancer progression, invasion, and metastasis. Stromal PTEN regulates ECM organization in the mammary gland, and its loss promotes a pro-tumorigenic matrix. Negative regulation of ECM organization can therefore suppress tumor growth by limiting matrix stiffness and pro-invasive signals.
Cardiovascular disease
After myocardial infarction, ECM remodeling is critical for scar formation. CCN1 promotes collagen alignment and scar integrity, but excessive or insufficient ECM organization can lead to cardiac rupture or fibrosis. Negative regulators help balance this process.
Neuromuscular disorders
Muscle satellite cell dysfunction in neuromuscular disorders involves altered ECM organization, and negative regulators may influence disease progression. However, direct evidence for GO:1903054 in these disorders is limited.
From negative regulation of extracellular matrix organization-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SFRP1 increase ECM deposition? | SFRP1 knockout in human lung fibroblasts |
| Does PTEN negatively regulate ECM organization in stroma? | Stromal PTEN knockout mouse |
| What is the role of CCN1 in post-MI ECM organization? | CCN1 overexpression or knockout in cardiac fibroblasts |
| How does paxillin phosphorylation affect matrix remodeling? | Point mutations in PXN in fibroblasts |
| Can CRISPR activation of MMPs reduce fibrosis? | Overexpression of MMP2/MMP9 in fibrotic models |
| What genes negatively regulate ECM in ovarian cancer? | CRISPR library screening in ovarian cancer cells |
How to Study the negative regulation of extracellular matrix organization Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify ECM genes regulated by candidate factors |
| Proteomics | Protein abundance and modifications | Quantify ECM composition |
| Immunofluorescence | Protein localization and matrix structure | Visualize collagen and fibronectin organization |
| Second harmonic generation | Collagen fibril organization | Assess matrix alignment in tissues |
| Invasion assay | Cell invasive capacity | Test negative regulators of ECM invasion |
| CRISPR screen | Gene function at scale | Discover novel negative regulators of ECM organization |
| Bioinformatics | Pathway and network analysis | Integrate omics data to infer regulatory mechanisms |
Transcriptomics and RNA-seq
RNA sequencing can identify changes in ECM gene expression upon manipulation of candidate negative regulators. For example, SFRP1 knockdown leads to increased expression of pro-fibrotic genes. Bioinformatics analysis of GEO datasets can reveal prognostic signatures related to ECM organization.
Proteomics and secretome analysis
Mass spectrometry-based proteomics can quantify ECM protein deposition and secretion. This is useful for assessing the impact of negative regulators on matrix composition.
Imaging and histology
Immunofluorescence and second harmonic generation microscopy visualize collagen organization and matrix architecture. These methods are essential for confirming functional changes in ECM organization.
Functional assays
Cell invasion, migration, and contraction assays measure the functional consequences of altered ECM organization. For instance, SFRP1 inhibits fibroblast invasion in vitro.
How CRISPR Can Be Used to Study GO:1903054 negative regulation of extracellular matrix organization
Knockout
CRISPR knockout of candidate negative regulators such as SFRP1 or PTEN can be used to test whether their loss increases ECM organization. For example, SFRP1 knockout in lung fibroblasts may enhance myofibroblast transition and matrix deposition. PTEN knockout in stromal cells leads to increased ECM organization.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites. For instance, mutating paxillin phosphorylation sites can reveal their role in cell migration and matrix remodeling. This approach provides mechanistic insights beyond simple knockout.
Knock-in
Knock-in of tagged versions of ECM regulators allows for live-cell imaging and interaction studies. Tagged CCN1 could be used to track its secretion and incorporation into the matrix after myocardial infarction.
Overexpression
Overexpression of negative regulators such as SFRP1 or CCN1 can suppress ECM organization and reduce fibrosis in disease models. This is useful for validating therapeutic potential.
How EDITGENE Supports negative regulation of extracellular matrix organization Research
Researchers studying negative regulation of extracellular matrix organization-related genes often need to determine whether a candidate gene is causally involved in matrix remodeling or simply correlated with disease. EDITGENE provides comprehensive CRISPR-based services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of extracellular matrix organization research.
Frequently Asked Questions About negative regulation of extracellular matrix organization
What is GO:1903054?
GO:1903054 is a Gene Ontology term for negative regulation of extracellular matrix organization, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of ECM organization.
What genes are involved in negative regulation of extracellular matrix organization?
Key genes include SFRP1, PTEN, CCN1, MMP2, MMP9, and PXN, among others.
How is negative regulation of ECM organization studied?
Common methods include CRISPR knockout, overexpression, RNA-seq, proteomics, and imaging of matrix structure.
Why is negative regulation of ECM organization important in cancer?
It helps limit tumor-promoting matrix stiffness and invasion; loss of negative regulators like PTEN can enhance ECM deposition and cancer progression.
What diseases are linked to dysregulated ECM organization?
Fibrosis, cancer, cardiovascular disease, and neuromuscular disorders are associated with altered ECM organization.
What is the role of SFRP1 in ECM organization?
SFRP1 inhibits lung fibroblast invasion and myofibroblast transition, acting as a negative regulator of ECM organization.
How does PTEN regulate ECM organization?
Stromal PTEN negatively regulates ECM organization in the mammary gland; its loss leads to increased matrix deposition.
Can CRISPR be used to study negative regulation of ECM organization?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function in ECM regulation.
What is the relationship between CCN1 and ECM organization?
CCN1 promotes collagen alignment and scar integrity after myocardial infarction, modulating ECM organization.
How can I find novel negative regulators of ECM organization?
CRISPR library screening combined with bioinformatics can identify novel regulators from genome-wide screens.
Conclusion
GO:1903054, negative regulation of extracellular matrix organization, is a critical biological process that maintains tissue homeostasis by restraining excessive matrix deposition. Its dysregulation contributes to fibrosis, cancer, and cardiovascular disease. Understanding the genes and mechanisms involved offers therapeutic opportunities. EDITGENE provides comprehensive CRISPR services to accelerate research in this field.
References
- 1. Mayr CH et al.. 2024. Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts.. Eur Respir J 63(2) PMID: 38212077
- 2. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 3. Turner CE. 2000. Paxillin interactions.. J Cell Sci 113 Pt 23:4139-40 PMID: 11069756
- 4. Fischer AG et al.. 2024. Matricellular protein CCN1 promotes collagen alignment and scar integrity after myocardial infarction.. Matrix Biol 133:14-32 PMID: 39098433
- 5. Marastoni S et al.. 2008. Extracellular matrix: a matter of life and death.. Connect Tissue Res 49(3):203-6 PMID: 18661343
- 6. Jones CE et al.. 2019. Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland.. Neoplasia 21(1):132-145 PMID: 30550871
- 7. Li Y et al.. 2019. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.. J Ovarian Res 12(1):106 PMID: 31703725
